Sun Pharma and Moebius Medical Announce Fast Track Designation Granted for MM-II for the Treatment of Osteoarthritis Knee Pain
Sun Pharma and Israel-based Moebius Medical Limited announced that the U.S. Food and Drug Administration has granted Fast Track designation to MM-II Large Liposomes of DPPC and DMPC for the treatment of osteoarthritis knee pain. Planning for confirmatory Phase 3 clinical trials for MM- II is underway.